nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—TYK2—type 1 diabetes mellitus	0.585	1	CbGaD
Crizotinib—ACVR1—pes—type 1 diabetes mellitus	0.00758	0.0564	CbGeAlD
Crizotinib—TESK1—Enalapril—Ramipril—type 1 diabetes mellitus	0.00367	1	CbGdCrCtD
Crizotinib—BMPR1B—peripheral nervous system—type 1 diabetes mellitus	0.0031	0.0231	CbGeAlD
Crizotinib—INSRR—kidney—type 1 diabetes mellitus	0.00308	0.0229	CbGeAlD
Crizotinib—Polyneuropathy—Ramipril—type 1 diabetes mellitus	0.00268	0.142	CcSEcCtD
Crizotinib—MAP3K3—peripheral nervous system—type 1 diabetes mellitus	0.00196	0.0146	CbGeAlD
Crizotinib—EPHA4—nerve—type 1 diabetes mellitus	0.00183	0.0136	CbGeAlD
Crizotinib—PRKD3—islet of Langerhans—type 1 diabetes mellitus	0.00169	0.0126	CbGeAlD
Crizotinib—Balance disorder—Ramipril—type 1 diabetes mellitus	0.0016	0.0849	CcSEcCtD
Crizotinib—MET—islet of Langerhans—type 1 diabetes mellitus	0.00146	0.0109	CbGeAlD
Crizotinib—PRKD1—nephron tubule—type 1 diabetes mellitus	0.00141	0.0105	CbGeAlD
Crizotinib—NEK9—cardiovascular system—type 1 diabetes mellitus	0.00139	0.0104	CbGeAlD
Crizotinib—NEK9—kidney—type 1 diabetes mellitus	0.00136	0.0101	CbGeAlD
Crizotinib—ACVR1B—islet of Langerhans—type 1 diabetes mellitus	0.00135	0.01	CbGeAlD
Crizotinib—MAPK7—retina—type 1 diabetes mellitus	0.00133	0.00992	CbGeAlD
Crizotinib—PRKD1—cardiovascular system—type 1 diabetes mellitus	0.00127	0.00945	CbGeAlD
Crizotinib—Burning sensation—Ramipril—type 1 diabetes mellitus	0.00126	0.0668	CcSEcCtD
Crizotinib—Neuralgia—Ramipril—type 1 diabetes mellitus	0.00126	0.0668	CcSEcCtD
Crizotinib—MET—retina—type 1 diabetes mellitus	0.00125	0.00929	CbGeAlD
Crizotinib—PRKD1—kidney—type 1 diabetes mellitus	0.00124	0.00925	CbGeAlD
Crizotinib—PRKD3—kidney—type 1 diabetes mellitus	0.00119	0.00889	CbGeAlD
Crizotinib—PRKD3—pancreas—type 1 diabetes mellitus	0.00119	0.00883	CbGeAlD
Crizotinib—NEK9—lymphoid tissue—type 1 diabetes mellitus	0.00117	0.00871	CbGeAlD
Crizotinib—EPHA3—retina—type 1 diabetes mellitus	0.00115	0.00859	CbGeAlD
Crizotinib—MAPK7—cardiovascular system—type 1 diabetes mellitus	0.00113	0.00839	CbGeAlD
Crizotinib—MAPK7—pancreas—type 1 diabetes mellitus	0.0011	0.00816	CbGeAlD
Crizotinib—TESK1—islet of Langerhans—type 1 diabetes mellitus	0.00108	0.00803	CbGeAlD
Crizotinib—MET—cardiovascular system—type 1 diabetes mellitus	0.00106	0.00786	CbGeAlD
Crizotinib—MET—kidney—type 1 diabetes mellitus	0.00103	0.00769	CbGeAlD
Crizotinib—MET—pancreas—type 1 diabetes mellitus	0.00103	0.00764	CbGeAlD
Crizotinib—NUAK2—islet of Langerhans—type 1 diabetes mellitus	0.00102	0.00761	CbGeAlD
Crizotinib—EPHA5—retina—type 1 diabetes mellitus	0.00102	0.0076	CbGeAlD
Crizotinib—ACVR1—islet of Langerhans—type 1 diabetes mellitus	0.00102	0.00756	CbGeAlD
Crizotinib—MAP4K1—retina—type 1 diabetes mellitus	0.001	0.00744	CbGeAlD
Crizotinib—STK35—islet of Langerhans—type 1 diabetes mellitus	0.000995	0.0074	CbGeAlD
Crizotinib—BLK—lymphoid tissue—type 1 diabetes mellitus	0.00099	0.00737	CbGeAlD
Crizotinib—ACVR1B—kidney—type 1 diabetes mellitus	0.000955	0.00711	CbGeAlD
Crizotinib—ACVR1B—pancreas—type 1 diabetes mellitus	0.000949	0.00706	CbGeAlD
Crizotinib—MAPK7—lymphoid tissue—type 1 diabetes mellitus	0.000948	0.00705	CbGeAlD
Crizotinib—TXK—lymphoid tissue—type 1 diabetes mellitus	0.000948	0.00705	CbGeAlD
Crizotinib—RIPK2—islet of Langerhans—type 1 diabetes mellitus	0.000918	0.00683	CbGeAlD
Crizotinib—MERTK—retina—type 1 diabetes mellitus	0.000898	0.00668	CbGeAlD
Crizotinib—MET—lymphoid tissue—type 1 diabetes mellitus	0.000888	0.0066	CbGeAlD
Crizotinib—TESK1—nephron tubule—type 1 diabetes mellitus	0.000869	0.00646	CbGeAlD
Crizotinib—ACVR1—retina—type 1 diabetes mellitus	0.000869	0.00646	CbGeAlD
Crizotinib—CDK7—lymphoid tissue—type 1 diabetes mellitus	0.000859	0.00639	CbGeAlD
Crizotinib—TBK1—islet of Langerhans—type 1 diabetes mellitus	0.000852	0.00634	CbGeAlD
Crizotinib—PTK2—islet of Langerhans—type 1 diabetes mellitus	0.000852	0.00634	CbGeAlD
Crizotinib—TYK2—islet of Langerhans—type 1 diabetes mellitus	0.000846	0.00629	CbGeAlD
Crizotinib—IRAK1—islet of Langerhans—type 1 diabetes mellitus	0.000835	0.00621	CbGeAlD
Crizotinib—IGF1R—cardiovascular system—type 1 diabetes mellitus	0.00083	0.00617	CbGeAlD
Crizotinib—NUAK2—nephron tubule—type 1 diabetes mellitus	0.000824	0.00613	CbGeAlD
Crizotinib—Neuropathy—Ramipril—type 1 diabetes mellitus	0.000821	0.0436	CcSEcCtD
Crizotinib—ACVR1—nephron tubule—type 1 diabetes mellitus	0.000818	0.00608	CbGeAlD
Crizotinib—IGF1R—kidney—type 1 diabetes mellitus	0.000812	0.00604	CbGeAlD
Crizotinib—TIE1—cardiovascular system—type 1 diabetes mellitus	0.000808	0.00601	CbGeAlD
Crizotinib—IGF1R—pancreas—type 1 diabetes mellitus	0.000807	0.006	CbGeAlD
Crizotinib—RIPK2—retina—type 1 diabetes mellitus	0.000785	0.00584	CbGeAlD
Crizotinib—JAK3—lymphoid tissue—type 1 diabetes mellitus	0.000783	0.00582	CbGeAlD
Crizotinib—SLK—islet of Langerhans—type 1 diabetes mellitus	0.000781	0.00581	CbGeAlD
Crizotinib—EPHB4—islet of Langerhans—type 1 diabetes mellitus	0.000775	0.00577	CbGeAlD
Crizotinib—PLK4—lymphoid tissue—type 1 diabetes mellitus	0.000773	0.00575	CbGeAlD
Crizotinib—AURKA—kidney—type 1 diabetes mellitus	0.00077	0.00573	CbGeAlD
Crizotinib—STK4—lymphoid tissue—type 1 diabetes mellitus	0.000768	0.00571	CbGeAlD
Crizotinib—EPHA2—islet of Langerhans—type 1 diabetes mellitus	0.000761	0.00566	CbGeAlD
Crizotinib—MAP4K5—islet of Langerhans—type 1 diabetes mellitus	0.000742	0.00552	CbGeAlD
Crizotinib—RIPK2—nephron tubule—type 1 diabetes mellitus	0.000739	0.0055	CbGeAlD
Crizotinib—ACVR1—cardiovascular system—type 1 diabetes mellitus	0.000735	0.00546	CbGeAlD
Crizotinib—FLT3—cardiovascular system—type 1 diabetes mellitus	0.000735	0.00546	CbGeAlD
Crizotinib—ALK—lymphoid tissue—type 1 diabetes mellitus	0.000726	0.0054	CbGeAlD
Crizotinib—TYRO3—lymphoid tissue—type 1 diabetes mellitus	0.000726	0.0054	CbGeAlD
Crizotinib—FER—lymphoid tissue—type 1 diabetes mellitus	0.000726	0.0054	CbGeAlD
Crizotinib—TYK2—retina—type 1 diabetes mellitus	0.000724	0.00538	CbGeAlD
Crizotinib—LYN—lymphoid tissue—type 1 diabetes mellitus	0.000722	0.00537	CbGeAlD
Crizotinib—NUAK2—pancreas—type 1 diabetes mellitus	0.000719	0.00535	CbGeAlD
Crizotinib—ACVR1—kidney—type 1 diabetes mellitus	0.000719	0.00535	CbGeAlD
Crizotinib—ACVR1—pancreas—type 1 diabetes mellitus	0.000714	0.00531	CbGeAlD
Crizotinib—MAP4K1—lymphoid tissue—type 1 diabetes mellitus	0.000711	0.00529	CbGeAlD
Crizotinib—EPHB6—islet of Langerhans—type 1 diabetes mellitus	0.000709	0.00527	CbGeAlD
Crizotinib—Hepatic failure—Ramipril—type 1 diabetes mellitus	0.000706	0.0375	CcSEcCtD
Crizotinib—RPS6KB1—retina—type 1 diabetes mellitus	0.000701	0.00521	CbGeAlD
Crizotinib—MAP3K2—nephron tubule—type 1 diabetes mellitus	0.0007	0.00521	CbGeAlD
Crizotinib—STK35—pancreas—type 1 diabetes mellitus	0.0007	0.0052	CbGeAlD
Crizotinib—IGF1R—lymphoid tissue—type 1 diabetes mellitus	0.000698	0.00519	CbGeAlD
Crizotinib—AXL—retina—type 1 diabetes mellitus	0.000694	0.00516	CbGeAlD
Crizotinib—MAP4K2—lymphoid tissue—type 1 diabetes mellitus	0.000688	0.00512	CbGeAlD
Crizotinib—TBK1—nephron tubule—type 1 diabetes mellitus	0.000686	0.0051	CbGeAlD
Crizotinib—PTK2—nephron tubule—type 1 diabetes mellitus	0.000686	0.0051	CbGeAlD
Crizotinib—YES1—islet of Langerhans—type 1 diabetes mellitus	0.000685	0.0051	CbGeAlD
Crizotinib—TYK2—nephron tubule—type 1 diabetes mellitus	0.000681	0.00507	CbGeAlD
Crizotinib—TAOK3—islet of Langerhans—type 1 diabetes mellitus	0.000677	0.00503	CbGeAlD
Crizotinib—IRAK1—nephron tubule—type 1 diabetes mellitus	0.000673	0.005	CbGeAlD
Crizotinib—PTK2B—cardiovascular system—type 1 diabetes mellitus	0.000669	0.00498	CbGeAlD
Crizotinib—RIPK2—cardiovascular system—type 1 diabetes mellitus	0.000664	0.00494	CbGeAlD
Crizotinib—AURKA—lymphoid tissue—type 1 diabetes mellitus	0.000661	0.00492	CbGeAlD
Crizotinib—SRC—islet of Langerhans—type 1 diabetes mellitus	0.000659	0.0049	CbGeAlD
Crizotinib—PTK2B—kidney—type 1 diabetes mellitus	0.000655	0.00487	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—type 1 diabetes mellitus	0.000638	0.00475	CbGeAlD
Crizotinib—SLK—nephron tubule—type 1 diabetes mellitus	0.000629	0.00468	CbGeAlD
Crizotinib—EPHB4—nephron tubule—type 1 diabetes mellitus	0.000624	0.00464	CbGeAlD
Crizotinib—LIMK2—lymphoid tissue—type 1 diabetes mellitus	0.000624	0.00464	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—type 1 diabetes mellitus	0.000617	0.00459	CbGeAlD
Crizotinib—PTK2—cardiovascular system—type 1 diabetes mellitus	0.000616	0.00458	CbGeAlD
Crizotinib—TBK1—cardiovascular system—type 1 diabetes mellitus	0.000616	0.00458	CbGeAlD
Crizotinib—EPHA2—nephron tubule—type 1 diabetes mellitus	0.000612	0.00456	CbGeAlD
Crizotinib—TYK2—cardiovascular system—type 1 diabetes mellitus	0.000612	0.00455	CbGeAlD
Crizotinib—PTK2—kidney—type 1 diabetes mellitus	0.000603	0.00448	CbGeAlD
Crizotinib—TBK1—kidney—type 1 diabetes mellitus	0.000603	0.00448	CbGeAlD
Crizotinib—TBK1—pancreas—type 1 diabetes mellitus	0.000599	0.00445	CbGeAlD
Crizotinib—PTK2—pancreas—type 1 diabetes mellitus	0.000599	0.00445	CbGeAlD
Crizotinib—TYK2—kidney—type 1 diabetes mellitus	0.000599	0.00445	CbGeAlD
Crizotinib—MAP3K3—nephron tubule—type 1 diabetes mellitus	0.000597	0.00444	CbGeAlD
Crizotinib—TYK2—pancreas—type 1 diabetes mellitus	0.000595	0.00442	CbGeAlD
Crizotinib—RPS6KB1—cardiovascular system—type 1 diabetes mellitus	0.000593	0.00441	CbGeAlD
Crizotinib—FGR—cardiovascular system—type 1 diabetes mellitus	0.000589	0.00438	CbGeAlD
Crizotinib—IRAK1—pancreas—type 1 diabetes mellitus	0.000587	0.00437	CbGeAlD
Crizotinib—AXL—cardiovascular system—type 1 diabetes mellitus	0.000587	0.00436	CbGeAlD
Crizotinib—YES1—retina—type 1 diabetes mellitus	0.000586	0.00436	CbGeAlD
Crizotinib—RPS6KB1—kidney—type 1 diabetes mellitus	0.00058	0.00431	CbGeAlD
Crizotinib—TAOK3—retina—type 1 diabetes mellitus	0.000578	0.0043	CbGeAlD
Crizotinib—RPS6KB1—pancreas—type 1 diabetes mellitus	0.000576	0.00429	CbGeAlD
Crizotinib—SRC—retina—type 1 diabetes mellitus	0.000564	0.00419	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—type 1 diabetes mellitus	0.000562	0.00418	CbGeAlD
Crizotinib—EPHB4—cardiovascular system—type 1 diabetes mellitus	0.000561	0.00417	CbGeAlD
Crizotinib—JAK2—cardiovascular system—type 1 diabetes mellitus	0.000557	0.00414	CbGeAlD
Crizotinib—YES1—nephron tubule—type 1 diabetes mellitus	0.000552	0.0041	CbGeAlD
Crizotinib—EPHA2—cardiovascular system—type 1 diabetes mellitus	0.00055	0.00409	CbGeAlD
Crizotinib—SLK—pancreas—type 1 diabetes mellitus	0.000549	0.00408	CbGeAlD
Crizotinib—EPHB4—kidney—type 1 diabetes mellitus	0.000549	0.00408	CbGeAlD
Crizotinib—EPHB4—pancreas—type 1 diabetes mellitus	0.000545	0.00405	CbGeAlD
Crizotinib—JAK2—kidney—type 1 diabetes mellitus	0.000545	0.00405	CbGeAlD
Crizotinib—TAOK3—nephron tubule—type 1 diabetes mellitus	0.000545	0.00405	CbGeAlD
Crizotinib—TEK—cardiovascular system—type 1 diabetes mellitus	0.000537	0.00399	CbGeAlD
Crizotinib—MAP3K3—cardiovascular system—type 1 diabetes mellitus	0.000537	0.00399	CbGeAlD
Crizotinib—EPHA2—pancreas—type 1 diabetes mellitus	0.000535	0.00398	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—type 1 diabetes mellitus	0.000529	0.00393	CbGeAlD
Crizotinib—TEK—kidney—type 1 diabetes mellitus	0.000525	0.00391	CbGeAlD
Crizotinib—MAP4K5—pancreas—type 1 diabetes mellitus	0.000522	0.00388	CbGeAlD
Crizotinib—TEK—pancreas—type 1 diabetes mellitus	0.000522	0.00388	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—type 1 diabetes mellitus	0.000518	0.00385	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—type 1 diabetes mellitus	0.000518	0.00385	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—type 1 diabetes mellitus	0.000514	0.00383	CbGeAlD
Crizotinib—Neutropenia—Ramipril—type 1 diabetes mellitus	0.000513	0.0272	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Ramipril—type 1 diabetes mellitus	0.00051	0.0271	CcSEcCtD
Crizotinib—RPS6KB1—lymphoid tissue—type 1 diabetes mellitus	0.000498	0.00371	CbGeAlD
Crizotinib—FGR—lymphoid tissue—type 1 diabetes mellitus	0.000495	0.00368	CbGeAlD
Crizotinib—AXL—lymphoid tissue—type 1 diabetes mellitus	0.000493	0.00367	CbGeAlD
Crizotinib—STK10—cardiovascular system—type 1 diabetes mellitus	0.000491	0.00365	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—type 1 diabetes mellitus	0.000489	0.00364	CbGeAlD
Crizotinib—YES1—kidney—type 1 diabetes mellitus	0.000485	0.00361	CbGeAlD
Crizotinib—YES1—pancreas—type 1 diabetes mellitus	0.000482	0.00358	CbGeAlD
Crizotinib—STK10—kidney—type 1 diabetes mellitus	0.000481	0.00357	CbGeAlD
Crizotinib—Neuropathy peripheral—Ramipril—type 1 diabetes mellitus	0.000479	0.0254	CcSEcCtD
Crizotinib—TAOK3—kidney—type 1 diabetes mellitus	0.000479	0.00356	CbGeAlD
Crizotinib—SRC—cardiovascular system—type 1 diabetes mellitus	0.000477	0.00355	CbGeAlD
Crizotinib—TAOK3—pancreas—type 1 diabetes mellitus	0.000476	0.00354	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—type 1 diabetes mellitus	0.000468	0.00348	CbGeAlD
Crizotinib—ABL1—islet of Langerhans—type 1 diabetes mellitus	0.000468	0.00348	CbGeAlD
Crizotinib—SRC—kidney—type 1 diabetes mellitus	0.000467	0.00347	CbGeAlD
Crizotinib—SRC—pancreas—type 1 diabetes mellitus	0.000463	0.00345	CbGeAlD
Crizotinib—Hepatobiliary disease—Ramipril—type 1 diabetes mellitus	0.000462	0.0246	CcSEcCtD
Crizotinib—EPHA2—lymphoid tissue—type 1 diabetes mellitus	0.000462	0.00344	CbGeAlD
Crizotinib—TEK—lymphoid tissue—type 1 diabetes mellitus	0.000451	0.00335	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—type 1 diabetes mellitus	0.000451	0.00335	CbGeAlD
Crizotinib—Oedema peripheral—Ramipril—type 1 diabetes mellitus	0.000432	0.023	CcSEcCtD
Crizotinib—CSF1R—cardiovascular system—type 1 diabetes mellitus	0.000428	0.00318	CbGeAlD
Crizotinib—Visual impairment—Ramipril—type 1 diabetes mellitus	0.000423	0.0225	CcSEcCtD
Crizotinib—YES1—lymphoid tissue—type 1 diabetes mellitus	0.000417	0.0031	CbGeAlD
Crizotinib—STK10—lymphoid tissue—type 1 diabetes mellitus	0.000413	0.00307	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—type 1 diabetes mellitus	0.000411	0.00306	CbGeAlD
Crizotinib—SRC—lymphoid tissue—type 1 diabetes mellitus	0.000401	0.00298	CbGeAlD
Crizotinib—ABL1—retina—type 1 diabetes mellitus	0.0004	0.00298	CbGeAlD
Crizotinib—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.000396	0.021	CcSEcCtD
Crizotinib—Arrhythmia—Ramipril—type 1 diabetes mellitus	0.000392	0.0208	CcSEcCtD
Crizotinib—Malnutrition—Ramipril—type 1 diabetes mellitus	0.000382	0.0203	CcSEcCtD
Crizotinib—ABL1—nephron tubule—type 1 diabetes mellitus	0.000377	0.0028	CbGeAlD
Crizotinib—Dysgeusia—Ramipril—type 1 diabetes mellitus	0.000374	0.0199	CcSEcCtD
Crizotinib—CSF1R—lymphoid tissue—type 1 diabetes mellitus	0.00036	0.00268	CbGeAlD
Crizotinib—Syncope—Ramipril—type 1 diabetes mellitus	0.000343	0.0182	CcSEcCtD
Crizotinib—Leukopenia—Ramipril—type 1 diabetes mellitus	0.000342	0.0182	CcSEcCtD
Crizotinib—ABL1—cardiovascular system—type 1 diabetes mellitus	0.000338	0.00252	CbGeAlD
Crizotinib—Loss of consciousness—Ramipril—type 1 diabetes mellitus	0.000336	0.0178	CcSEcCtD
Crizotinib—ABL1—kidney—type 1 diabetes mellitus	0.000331	0.00246	CbGeAlD
Crizotinib—ABL1—pancreas—type 1 diabetes mellitus	0.000329	0.00245	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.000323	0.0172	CcSEcCtD
Crizotinib—Oedema—Ramipril—type 1 diabetes mellitus	0.000312	0.0166	CcSEcCtD
Crizotinib—Shock—Ramipril—type 1 diabetes mellitus	0.000307	0.0163	CcSEcCtD
Crizotinib—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.000306	0.0162	CcSEcCtD
Crizotinib—Skin disorder—Ramipril—type 1 diabetes mellitus	0.000303	0.0161	CcSEcCtD
Crizotinib—ABL1—lymphoid tissue—type 1 diabetes mellitus	0.000284	0.00212	CbGeAlD
Crizotinib—Paraesthesia—Ramipril—type 1 diabetes mellitus	0.00028	0.0149	CcSEcCtD
Crizotinib—Dyspnoea—Ramipril—type 1 diabetes mellitus	0.000278	0.0148	CcSEcCtD
Crizotinib—Dyspepsia—Ramipril—type 1 diabetes mellitus	0.000275	0.0146	CcSEcCtD
Crizotinib—CYP3A5—islet of Langerhans—type 1 diabetes mellitus	0.000274	0.00204	CbGeAlD
Crizotinib—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.000271	0.0144	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.000269	0.0143	CcSEcCtD
Crizotinib—Fatigue—Ramipril—type 1 diabetes mellitus	0.000269	0.0143	CcSEcCtD
Crizotinib—Constipation—Ramipril—type 1 diabetes mellitus	0.000267	0.0142	CcSEcCtD
Crizotinib—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.000247	0.0131	CcSEcCtD
Crizotinib—Asthenia—Ramipril—type 1 diabetes mellitus	0.000224	0.0119	CcSEcCtD
Crizotinib—CYP3A5—nephron tubule—type 1 diabetes mellitus	0.000221	0.00164	CbGeAlD
Crizotinib—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.000213	0.0113	CcSEcCtD
Crizotinib—Dizziness—Ramipril—type 1 diabetes mellitus	0.000206	0.0109	CcSEcCtD
Crizotinib—Vomiting—Ramipril—type 1 diabetes mellitus	0.000198	0.0105	CcSEcCtD
Crizotinib—Rash—Ramipril—type 1 diabetes mellitus	0.000197	0.0104	CcSEcCtD
Crizotinib—Dermatitis—Ramipril—type 1 diabetes mellitus	0.000196	0.0104	CcSEcCtD
Crizotinib—CYP3A5—kidney—type 1 diabetes mellitus	0.000194	0.00144	CbGeAlD
Crizotinib—CYP3A5—pancreas—type 1 diabetes mellitus	0.000193	0.00143	CbGeAlD
Crizotinib—Nausea—Ramipril—type 1 diabetes mellitus	0.000185	0.00983	CcSEcCtD
Crizotinib—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.000145	0.00108	CbGeAlD
Crizotinib—CYP3A4—kidney—type 1 diabetes mellitus	0.000145	0.00108	CbGeAlD
Crizotinib—ABCB1—retina—type 1 diabetes mellitus	0.000124	0.000925	CbGeAlD
Crizotinib—ABCB1—nephron tubule—type 1 diabetes mellitus	0.000117	0.000871	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.000105	0.000783	CbGeAlD
Crizotinib—ABCB1—kidney—type 1 diabetes mellitus	0.000103	0.000766	CbGeAlD
Crizotinib—ABCB1—pancreas—type 1 diabetes mellitus	0.000102	0.000761	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—type 1 diabetes mellitus	8.84e-05	0.000658	CbGeAlD
Crizotinib—TYK2—Signaling Pathways—CD80—type 1 diabetes mellitus	3.13e-06	1.22e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—type 1 diabetes mellitus	3.12e-06	1.21e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HLA-A—type 1 diabetes mellitus	3.12e-06	1.21e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—STAT3—type 1 diabetes mellitus	3.11e-06	1.21e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF1—type 1 diabetes mellitus	3.11e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—type 1 diabetes mellitus	3.11e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNG—type 1 diabetes mellitus	3.1e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—TYK2—type 1 diabetes mellitus	3.1e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GCG—type 1 diabetes mellitus	3.1e-06	1.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CASP3—type 1 diabetes mellitus	3.09e-06	1.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—type 1 diabetes mellitus	3.09e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—E2F1—type 1 diabetes mellitus	3.09e-06	1.2e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—type 1 diabetes mellitus	3.09e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCR5—type 1 diabetes mellitus	3.09e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DRB1—type 1 diabetes mellitus	3.08e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS2—type 1 diabetes mellitus	3.06e-06	1.19e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—INS—type 1 diabetes mellitus	3.05e-06	1.18e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CASP3—type 1 diabetes mellitus	3.05e-06	1.18e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—type 1 diabetes mellitus	3.04e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2RA—type 1 diabetes mellitus	3.04e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—type 1 diabetes mellitus	3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ITPR3—type 1 diabetes mellitus	2.99e-06	1.16e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—type 1 diabetes mellitus	2.98e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	2.98e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—type 1 diabetes mellitus	2.97e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD80—type 1 diabetes mellitus	2.97e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—type 1 diabetes mellitus	2.97e-06	1.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—INS—type 1 diabetes mellitus	2.96e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF2—type 1 diabetes mellitus	2.96e-06	1.15e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—STAT3—type 1 diabetes mellitus	2.95e-06	1.14e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.95e-06	1.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—type 1 diabetes mellitus	2.95e-06	1.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.94e-06	1.14e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.92e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.92e-06	1.13e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.91e-06	1.13e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.91e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—type 1 diabetes mellitus	2.9e-06	1.13e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GCG—type 1 diabetes mellitus	2.9e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VAV1—type 1 diabetes mellitus	2.89e-06	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.89e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL10—type 1 diabetes mellitus	2.89e-06	1.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.87e-06	1.11e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—type 1 diabetes mellitus	2.87e-06	1.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—STAT3—type 1 diabetes mellitus	2.86e-06	1.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.86e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TYK2—type 1 diabetes mellitus	2.86e-06	1.11e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.86e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD86—type 1 diabetes mellitus	2.85e-06	1.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.85e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—type 1 diabetes mellitus	2.85e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD80—type 1 diabetes mellitus	2.85e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.85e-06	1.1e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—type 1 diabetes mellitus	2.83e-06	1.1e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.83e-06	1.1e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—type 1 diabetes mellitus	2.83e-06	1.1e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.83e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—type 1 diabetes mellitus	2.82e-06	1.1e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.82e-06	1.09e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—type 1 diabetes mellitus	2.82e-06	1.09e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	2.82e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—type 1 diabetes mellitus	2.81e-06	1.09e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—type 1 diabetes mellitus	2.81e-06	1.09e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—INS—type 1 diabetes mellitus	2.81e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—type 1 diabetes mellitus	2.8e-06	1.09e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	2.8e-06	1.09e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—type 1 diabetes mellitus	2.78e-06	1.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—type 1 diabetes mellitus	2.77e-06	1.07e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—type 1 diabetes mellitus	2.77e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—type 1 diabetes mellitus	2.77e-06	1.07e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCC8—type 1 diabetes mellitus	2.76e-06	1.07e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—type 1 diabetes mellitus	2.76e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—type 1 diabetes mellitus	2.76e-06	1.07e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—type 1 diabetes mellitus	2.75e-06	1.07e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	2.75e-06	1.07e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—type 1 diabetes mellitus	2.74e-06	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.73e-06	1.06e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—type 1 diabetes mellitus	2.72e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—TYK2—type 1 diabetes mellitus	2.72e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—type 1 diabetes mellitus	2.71e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—E2F1—type 1 diabetes mellitus	2.71e-06	1.05e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—type 1 diabetes mellitus	2.7e-06	1.05e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—type 1 diabetes mellitus	2.69e-06	1.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—type 1 diabetes mellitus	2.68e-06	1.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.67e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.65e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—STAT3—type 1 diabetes mellitus	2.65e-06	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD80—type 1 diabetes mellitus	2.63e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—type 1 diabetes mellitus	2.63e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF2—type 1 diabetes mellitus	2.62e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—type 1 diabetes mellitus	2.6e-06	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—type 1 diabetes mellitus	2.6e-06	1.01e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.6e-06	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.6e-06	1.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—type 1 diabetes mellitus	2.59e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—type 1 diabetes mellitus	2.59e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—type 1 diabetes mellitus	2.58e-06	1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.57e-06	9.97e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.56e-06	9.94e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—type 1 diabetes mellitus	2.54e-06	9.86e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CD80—type 1 diabetes mellitus	2.54e-06	9.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.53e-06	9.81e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD86—type 1 diabetes mellitus	2.52e-06	9.79e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—type 1 diabetes mellitus	2.52e-06	9.78e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TYK2—type 1 diabetes mellitus	2.51e-06	9.72e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.49e-06	9.67e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—INS—type 1 diabetes mellitus	2.48e-06	9.64e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—type 1 diabetes mellitus	2.46e-06	9.55e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAT—type 1 diabetes mellitus	2.46e-06	9.53e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—type 1 diabetes mellitus	2.46e-06	9.53e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.45e-06	9.51e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.43e-06	9.42e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—type 1 diabetes mellitus	2.42e-06	9.4e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	2.41e-06	9.35e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—TYK2—type 1 diabetes mellitus	2.4e-06	9.32e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—type 1 diabetes mellitus	2.4e-06	9.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—INS—type 1 diabetes mellitus	2.4e-06	9.3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—E2F1—type 1 diabetes mellitus	2.4e-06	9.29e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.39e-06	9.29e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.39e-06	9.27e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.38e-06	9.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CD80—type 1 diabetes mellitus	2.37e-06	9.21e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.36e-06	9.16e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.33e-06	9.03e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—STAT3—type 1 diabetes mellitus	2.32e-06	9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.32e-06	8.99e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—STAT3—type 1 diabetes mellitus	2.31e-06	8.96e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—type 1 diabetes mellitus	2.29e-06	8.87e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—type 1 diabetes mellitus	2.28e-06	8.84e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.28e-06	8.83e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.27e-06	8.81e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—type 1 diabetes mellitus	2.27e-06	8.8e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—type 1 diabetes mellitus	2.27e-06	8.79e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.27e-06	8.79e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—type 1 diabetes mellitus	2.26e-06	8.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—type 1 diabetes mellitus	2.25e-06	8.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INS—type 1 diabetes mellitus	2.24e-06	8.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.24e-06	8.68e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.23e-06	8.64e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TYK2—type 1 diabetes mellitus	2.22e-06	8.61e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.21e-06	8.56e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.2e-06	8.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—type 1 diabetes mellitus	2.2e-06	8.55e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—type 1 diabetes mellitus	2.2e-06	8.54e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	2.19e-06	8.5e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—type 1 diabetes mellitus	2.19e-06	8.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—KCNJ11—type 1 diabetes mellitus	2.18e-06	8.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—type 1 diabetes mellitus	2.18e-06	8.45e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—type 1 diabetes mellitus	2.17e-06	8.43e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—type 1 diabetes mellitus	2.17e-06	8.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—STAT3—type 1 diabetes mellitus	2.17e-06	8.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.17e-06	8.42e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—type 1 diabetes mellitus	2.16e-06	8.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.16e-06	8.38e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.14e-06	8.31e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—type 1 diabetes mellitus	2.11e-06	8.18e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.1e-06	8.15e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—type 1 diabetes mellitus	2.1e-06	8.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD80—type 1 diabetes mellitus	2.08e-06	8.07e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—type 1 diabetes mellitus	2.06e-06	7.99e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.04e-06	7.91e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—type 1 diabetes mellitus	2.04e-06	7.9e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—type 1 diabetes mellitus	2.02e-06	7.83e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—type 1 diabetes mellitus	2.01e-06	7.8e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—type 1 diabetes mellitus	2.01e-06	7.79e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—type 1 diabetes mellitus	2.01e-06	7.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TYK2—type 1 diabetes mellitus	2e-06	7.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—type 1 diabetes mellitus	2e-06	7.77e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—type 1 diabetes mellitus	2e-06	7.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—type 1 diabetes mellitus	2e-06	7.76e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—type 1 diabetes mellitus	1.97e-06	7.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.97e-06	7.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—type 1 diabetes mellitus	1.97e-06	7.62e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.91e-06	7.4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—type 1 diabetes mellitus	1.9e-06	7.37e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.9e-06	7.37e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	1.85e-06	7.19e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.85e-06	7.19e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.85e-06	7.18e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—type 1 diabetes mellitus	1.85e-06	7.17e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ITPR3—type 1 diabetes mellitus	1.84e-06	7.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD80—type 1 diabetes mellitus	1.84e-06	7.14e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.83e-06	7.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—type 1 diabetes mellitus	1.82e-06	7.07e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—type 1 diabetes mellitus	1.82e-06	7.04e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—type 1 diabetes mellitus	1.79e-06	6.94e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.79e-06	6.92e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—type 1 diabetes mellitus	1.78e-06	6.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.76e-06	6.81e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—type 1 diabetes mellitus	1.76e-06	6.81e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—type 1 diabetes mellitus	1.74e-06	6.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HBA1—type 1 diabetes mellitus	1.74e-06	6.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.73e-06	6.73e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—type 1 diabetes mellitus	1.73e-06	6.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOC3—type 1 diabetes mellitus	1.73e-06	6.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.72e-06	6.68e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.71e-06	6.64e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—type 1 diabetes mellitus	1.69e-06	6.57e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—type 1 diabetes mellitus	1.68e-06	6.53e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.68e-06	6.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.68e-06	6.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.67e-06	6.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—type 1 diabetes mellitus	1.67e-06	6.47e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.66e-06	6.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—type 1 diabetes mellitus	1.66e-06	6.44e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—type 1 diabetes mellitus	1.63e-06	6.33e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—type 1 diabetes mellitus	1.62e-06	6.28e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—type 1 diabetes mellitus	1.61e-06	6.26e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—type 1 diabetes mellitus	1.6e-06	6.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.55e-06	6.03e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—type 1 diabetes mellitus	1.55e-06	6.03e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—type 1 diabetes mellitus	1.53e-06	5.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.53e-06	5.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—type 1 diabetes mellitus	1.52e-06	5.88e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.5e-06	5.82e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—type 1 diabetes mellitus	1.5e-06	5.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.46e-06	5.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—type 1 diabetes mellitus	1.46e-06	5.67e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—type 1 diabetes mellitus	1.43e-06	5.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—type 1 diabetes mellitus	1.42e-06	5.53e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—type 1 diabetes mellitus	1.41e-06	5.48e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.41e-06	5.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.4e-06	5.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—type 1 diabetes mellitus	1.4e-06	5.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.36e-06	5.29e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCG—type 1 diabetes mellitus	1.35e-06	5.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.33e-06	5.17e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—type 1 diabetes mellitus	1.33e-06	5.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.3e-06	5.02e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—type 1 diabetes mellitus	1.29e-06	5.02e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—type 1 diabetes mellitus	1.29e-06	5.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.28e-06	4.95e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—type 1 diabetes mellitus	1.23e-06	4.77e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.23e-06	4.77e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—type 1 diabetes mellitus	1.23e-06	4.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—type 1 diabetes mellitus	1.18e-06	4.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—type 1 diabetes mellitus	1.14e-06	4.43e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	1.13e-06	4.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.12e-06	4.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.09e-06	4.22e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—type 1 diabetes mellitus	1.09e-06	4.21e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	1.08e-06	4.19e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—type 1 diabetes mellitus	1.05e-06	4.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—type 1 diabetes mellitus	9.89e-07	3.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—type 1 diabetes mellitus	9.81e-07	3.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—type 1 diabetes mellitus	8.59e-07	3.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—type 1 diabetes mellitus	7.6e-07	2.95e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—type 1 diabetes mellitus	7.59e-07	2.94e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—type 1 diabetes mellitus	6.95e-07	2.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—type 1 diabetes mellitus	6.65e-07	2.58e-06	CbGpPWpGaD
